Biological E

Biological E. Limited is an Indian biotechnology and biopharmaceutical company headquartered in Hyderabad, Telangana. Established in 1953 as Biological Products Private Limited, it was one of the early private-sector manufacturers of biological products in India. The company developed a business around vaccines, antisera, pharmaceutical formulations and other biological medicines, with a long-term emphasis on producing products at comparatively accessible prices for large populations. The company’s early history included the development of heparin manufacturing in India. During the 1960s and 1970s, it expanded its product activities into cough and digestive-enzyme formulations, anti-tetanus serum, anti-tuberculosis medicines, tetanus toxoid and diphtheria-tetanus-pertussis vaccines. This progression helped establish Biological E. as a domestic manufacturer serving public-health and pharmaceutical needs rather than solely as a research-oriented biotechnology enterprise. In 1964, Evans Medicals, a United Kingdom pharmaceutical company that was later merged into GlaxoSmithKline, acquired a 40% interest in Biological E. The promoters subsequently bought back that stake in 1995. The ownership history linked the company to an international pharmaceutical partner for part of its development, while the later buyback restored promoter ownership of the interest acquired by Evans Medicals. Vaccines became central to the company’s identity and international business. Biological E. began manufacturing its pentavalent vaccine, combining protection against diphtheria, tetanus, pertussis, Haemophilus influenzae type b and hepatitis B, in 2008. The company has supplied vaccines to international development and aid organizations, including organizations associated with the World Health Organization, UNICEF and the Bill & Melinda Gates Foundation. Its stated business model combines large-scale manufacturing with an emphasis on affordability and access. During the COVID-19 pandemic, Biological E. entered into development and manufacturing collaborations for COVID-19 vaccines. It partnered with Baylor College of Medicine, Texas Children's Hospital and Dynavax Technologies on the recombinant-protein vaccine later known as Corbevax. The company also signed an agreement with Johnson & Johnson in August 2020 to manufacture the Janssen vaccine candidate at its Hyderabad facility. In February 2021, Biological E. announced plans to produce more than 600 million doses of the single-dose Janssen vaccine annually. Corbevax was developed with the expectation of large-scale production, including planned output of approximately 75 million to 80 million doses per month and a target of up to one billion doses by the end of 2022 under the Quad initiative. Biological E. remains an active private Indian vaccine and biopharmaceutical manufacturer. Its principal public profile rests on vaccine production, contract and partnership manufacturing, and the development of biologics intended for broad access. Detailed current information on its full product portfolio, leadership roster, ownership structure and present manufacturing volumes is not established in the supplied reference material.

Biological E. Limited was founded in 1953 by Dr. D.V.K. Raju and G.A.N. Raju under the name Biological Products Private Limited. Its creation placed it among the first private-sector Indian companies manufacturing biological products. The company’s early development was associated with domestic production of specialized biological medicines, including heparin, which it pioneered in India. During the 1960s and 1970s, Biological E. broadened its activities beyond a single biological product. It developed cough and digestive-enzyme formulations, began producing anti-tetanus serum, and introduced anti-tuberculosis drugs as well as tetanus toxoid and diphtheria-tetanus-pertussis vaccines. These activities reflected the company’s evolution from an early biological-products manufacturer into a diversified pharmaceutical and vaccine business. In 1964, Evans Medicals, a United Kingdom pharmaceutical company, acquired a 40% stake in Biological E. Evans Medicals was later merged into GlaxoSmithKline. Biological E. subsequently bought back the stake held by the promoters in 1995, ending that phase of external strategic ownership. The company continued its development as an Indian private enterprise. Vaccines gradually became the central focus of Biological E.’s business. The company adopted a specialization in low-cost vaccine manufacturing and began producing its pentavalent vaccine in 2008. The product combines protection against diphtheria, tetanus, pertussis, Haemophilus influenzae type b and hepatitis B. Its vaccine manufacturing activities also supported supply relationships with international development and aid organizations, including the World Health Organization, UNICEF and the Bill & Melinda Gates Foundation. The COVID-19 pandemic created a new phase of partnerships and manufacturing expansion. In 2020, Biological E. entered an agreement with Johnson & Johnson to manufacture the Janssen COVID-19 vaccine candidate at its Hyderabad site. The company announced in February 2021 that it expected to produce more than 600 million doses of the single-dose vaccine each year. Biological E. also joined a development collaboration involving Baylor College of Medicine, Texas Children's Hospital and Dynavax Technologies. The collaboration produced the Corbevax recombinant-protein COVID-19 vaccine. Plans described during the pandemic called for production of approximately 75 million to 80 million doses per month, with an ambition to reach one billion doses by the end of 2022 under the Quad initiative. The company’s documented history therefore follows three broad stages: early domestic biological-product manufacturing, diversification into medicines and traditional vaccines, and expansion into high-volume vaccine production and international public-health partnerships. It remains an active private company based in Hyderabad, although the supplied references do not provide a complete current account of its ownership, leadership, product approvals or operating results.

1. 2021Large-scale Janssen production plans announced

   Biological E. announced plans to produce more than 600 million single-dose Janssen vaccine doses annually.

   Source
2. 2020Janssen manufacturing agreement

   The company signed an agreement with Johnson & Johnson to manufacture its COVID-19 vaccine candidate in Hyderabad.

   Source
3. 2008Pentavalent vaccine manufacturing begins

   Biological E. began manufacturing its pentavalent DTP-Hib-HepB vaccine.

   Source
4. 1995Promoters buy back Evans Medicals' stake

   The promoters bought back the 40% interest previously acquired by Evans Medicals.

   Source
5. 1970Expansion into vaccines and biological medicines

   During the 1960s and 1970s, the company developed formulations and manufactured anti-tetanus serum, anti-tuberculosis drugs, tetanus toxoid and DTP vaccines.

   Source
6. 1964Evans Medicals acquires a 40% stake

   United Kingdom pharmaceutical company Evans Medicals acquired a 40% interest in Biological E.

   Source
7. 1953Company founded as Biological Products Private Limited

   Dr. D.V.K. Raju and G.A.N. Raju founded the company in India, making it one of the early private-sector manufacturers of biological products.

   Source

Indian vaccine and biopharmaceutical manufacturer positioned around affordable, high-volume production and public-health access.

• Pentavalent vaccineCombination vaccine2008

  Biological E.'s pentavalent vaccine combines protection against diphtheria, tetanus, pertussis, Haemophilus influenzae type b and hepatitis B. Manufacturing began in 2008 and the product represents the company's shift toward high-volume, affordable immunization products for domestic and international public-health use.

• CorbevaxCOVID-19 vaccine

  Corbevax is a recombinant-protein COVID-19 vaccine developed through collaboration involving Biological E., Baylor College of Medicine, Texas Children's Hospital and Dynavax Technologies. During the pandemic, Biological E. planned large-scale manufacturing, with projected output of approximately 75 million to 80 million doses per month in the supplied reference material.

• Janssen COVID-19 vaccine manufacturingContract vaccine manufacturing

  Biological E. entered an agreement with Johnson & Johnson to manufacture the single-dose Janssen COVID-19 vaccine at its Hyderabad facility. The company announced plans in 2021 to produce more than 600 million doses annually.

• HeparinBiological medicine

  Biological E. is described as having pioneered heparin production in India. The supplied references identify this as an important early contribution but do not provide a product launch date or current commercial details.

• Anti-tetanus serumAntiserum

  Anti-tetanus serum was among the biological products the company began manufacturing during its expansion in the 1960s and 1970s.

• 2020Agreement with Johnson & Johnson for Janssen manufacturingM&A

  The COVID-19 pandemic created demand for geographically distributed vaccine manufacturing capacity.

  What changed. Biological E. agreed to manufacture Johnson & Johnson's vaccine candidate at its Hyderabad facility.

  Aftermath. In February 2021, the company announced an expected annual manufacturing capacity of more than 600 million doses for the single-dose Janssen vaccine.

  Source
• 2020Corbevax development collaborationProduct launch

  Biological E. sought to contribute to COVID-19 vaccine development and large-scale access during the pandemic.

  What changed. The company partnered with Baylor College of Medicine, Texas Children's Hospital and Dynavax Technologies to develop and manufacture the Corbevax vaccine.

  Aftermath. Production plans described in the supplied material targeted approximately 75 million to 80 million doses per month and up to one billion doses by the end of 2022 under the Quad initiative.

  Source
• 2008Scale-up of pentavalent vaccine manufacturingProduct launch

  Biological E. was pursuing a stronger specialization in low-cost, high-volume vaccine production.

  What changed. The company began manufacturing a pentavalent vaccine covering diphtheria, tetanus, pertussis, Haemophilus influenzae type b and hepatitis B.

  Aftermath. The product became a representative part of Biological E.'s vaccine-focused business and its public-health supply profile.

  Source

• 2021Biological E. announces planned annual production of more than 600 million Janssen doses

  The company announced plans to manufacture more than 600 million doses of Johnson & Johnson's single-dose Janssen vaccine annually.

  Product generationOther
  Source
• 2021Biological E. advances Corbevax COVID-19 vaccine development

  Through collaborations with Baylor College of Medicine, Texas Children's Hospital and Dynavax Technologies, Biological E. worked on development and large-scale manufacture of the protein-based Corbevax vaccine.

  Product launchOther
  Source
• 2020Biological E. signs COVID-19 vaccine manufacturing agreement with Johnson & Johnson

  Biological E. agreed to manufacture Johnson & Johnson's COVID-19 vaccine candidate at its Hyderabad facility during the pandemic.

  Product launchOther
  Source

1. Biological E. Limited
2. Biological E. Limited official website